Modulation of glycine receptor function by the synthetic cannabinoid HU210

Pharmacology

Volumn 83, Issue 5, 2009, Pages 270-274

  Demir, Reyhan ^a   Leuwer, Martin ^b   De La Roche, Jeanne ^a   Krampfl, Klaus ^a   Foadi, Nilufar ^a   Karst, Matthias ^a   Dengler, Reinhard ^a   Haeseler, Gertrud ^a   Ahrens, Jörg ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Anti nociceptive; Cannabinoids; Glycine receptor; HU210; Inhibitory synaptic transmission

Indexed keywords

DEXANABINOL; GLYCINE RECEPTOR;

ARTICLE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ALLOSTERIC REGULATION; CELL LINE, TRANSFORMED; GLYCINE; HUMANS; MEMBRANE POTENTIALS; RECEPTORS, GLYCINE; TETRAHYDROCANNABINOL; TRANSFECTION;

EID: 62649157764     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000209291     Document Type: Article

References (33)

1. Costa B: On the pharmacological properties of Delta9-tetrahydrocannabinol (THC). Chem Biodivers 2007;4:1664-1677.
2. McCarberg BH, Barkin RL: The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview. Am J Ther 2007;14:475-483.
3. Martin-Calderon JL, Munoz RM, Villanua MA, et al: Characterization of the acute endocrine actions of (-)-11-hydroxy-delta8-tetrahydrocannabinol- dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats. Eur J Pharmacol 1998;344:77-86.
4. Smith SR, Terminelli C, Denhardt G: Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 2000;293:136-150.
5. Martin WJ, Tsou K, Walker JM: Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci Lett 1998;242:33-36.
6. Knabl J, Witschi R, Hosl K, et al: Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature 2008; 451:330-334.
7. Betz H, Laube B: Glycine receptors: recent insights into their structural organization and functional diversity. J Neurochem 2006; 97:1600-1610.
8. Bolay H, Moskowitz MA: Mechanisms of pain modulation in chronic syndromes. Neurology 2002;59:S2-S7.
9. Laube B, Maksay G, Schemm R, Betz H: Modulation of glycine receptor function: a novel approach for therapeutic intervention at inhibitory synapses? Trends Pharmacol Sci 2002;23:519-527.
10. Geiman EJ, Zheng W, Fritschy JM, Alvarez FJ: Glycine and GABA(A) receptor subunits on Renshaw cells: relationship with presynaptic neurotransmitters and postsynaptic gephyrin clusters. J Comp Neurol 2002;444: 275-289.
11. Todd AJ, Watt C, Spike RC, Sieghart W: Co-localization of GABA, glycine, and their receptors at synapses in the rat spinal cord. J Neurosci 1996;16:974-982.
12. Zeilhofer HU: The glycinergic control of spinal pain processing. Cell Mol Life Sci 2005;62:2027-2035.
13. Lynch JW, Callister RJ: Glycine receptors: a new therapeutic target in pain pathways. Curr Opin Investig Drugs 2006;7:48-53.
14. Ahrens J, Leuwer M, Demir R, et al: Positive allosteric modulatory effects of ajulemic acid at strychnine-sensitive glycine alpha(1)- and alpha (1)beta-receptors. Naunyn Schmiedebergs Arch Pharmacol 2008.
15. Hejazi N, Zhou C, Oz M, et al: Delta9-tetra-hydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors. Mol Pharmacol 2006;69:991-997.
16. Mihic SJ, Ye Q, Wick MJ, et al: Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. Nature 1997;389:385-389.
17. Hamill OP, Marty A, Neher E, et al: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflügers Arch 1981;391:85-100.
18. Franke C, Hatt H, Dudel J: Liquid filament switch for ultra-fast exchanges of solutions at excised patches of synaptic membrane of crayf ish muscle. Neurosci Lett 1987;77:199-204.
19. Weir CJ, Ling AT, Belelli D, et al: The interaction of anaesthetic steroids with recombinant glycine and GABAA receptors. Br J Anaesth 2004;92:704-711.
20. Jentsch TJ, Stein V, Weinreich F, Zdebik AA: Molecular structure and physiological function of chloride channels. Physiol Rev 2002; 82:503-568.
21. Coull JA, Boudreau D, Bachand K, et al: Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature 2003;424:938-942.
22. Ahmadi S, Lippross S, Neuhuber WL, Zeilhofer HU: PGE(2) selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons. Nat Neurosci 2002;5:34-40.
23. Moore KA, Kohno T, Karchewski LA, et al: Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. J Neurosci 2002;22:6724-6731.
24. Pellicer F, Lopez-Avila A, Coffeen U, et al: Taurine in the anterior cingulate cortex diminishes neuropathic nociception: a possible interaction with the glycine(A) receptor. Eur J Pain 2007;11:444-451.
25. Harvey RJ, Depner UB, Wassle H, et al: GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science 2004;304: 884-887.
26. Agarwal N, Pacher P, Tegeder I, et al: Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007;10:870-879.
27. Iatsenko NM, Tsintsadze T, Lozova NO: [The synthetic cannabinoid analog WIN 55,212-2 potentiates the amplitudes of glycine-activated currents]. Fiziol Zh 2007;53: 31-37.
28. Tao Q, McAllister SD, Andreassi J, et al: Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity. Mol Pharmacol 1999;55:605-613.
29. Guindon J, Hohmann AG: Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 2008;153:319-334.
30. Dyson A, Peacock M, Chen A, et al: Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain 2005;116:129-137.
31. Cheng Y, Hitchcock SA: Targeting cannabinoid agonists for inflammatory and neuropathic pain. Expert Opin Investig Drugs 2007;16:951-965.
32. Klein TW: Cannabinoid-based drugs as antiinflammatory therapeutics. Nat Rev Immunol 2005;5: 400-411.
33. Ashton JC: Cannabinoids for the treatment of inflammation. Curr Opin Investig Drugs 2007;8:373-384.